Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 6.31M | 5.32M | 4.24M | 1.53M | 1.02M | 719.52K |
Gross Profit | 4.23M | 3.69M | 3.06M | 832.52K | 299.88K | -6.40K |
EBITDA | -9.51M | -11.68M | -9.93M | -11.52M | -11.67M | -9.25M |
Net Income | -3.25M | -7.18M | -6.25M | -9.11M | -9.04M | -6.15M |
Balance Sheet | ||||||
Total Assets | 40.04M | 26.62M | 29.61M | 37.90M | 19.33M | 23.17M |
Cash, Cash Equivalents and Short-Term Investments | 30.84M | 20.61M | 24.82M | 11.02M | 16.33M | 20.44M |
Total Debt | 657.93K | 689.69K | 562.30K | 507.56K | 621.72K | 500.89K |
Total Liabilities | 20.40M | 22.08M | 23.46M | 27.99M | 2.46M | 2.27M |
Stockholders Equity | 19.64M | 4.53M | 6.15M | 9.90M | 16.87M | 20.90M |
Cash Flow | ||||||
Free Cash Flow | -8.06M | -7.45M | 13.96M | -6.80M | -4.82M | -5.31M |
Operating Cash Flow | -7.34M | -6.51M | 14.59M | -6.26M | -4.63M | -5.26M |
Investing Cash Flow | -733.05K | -942.02K | -631.56K | -535.02K | -188.52K | -55.20K |
Financing Cash Flow | 19.29M | 3.24M | -164.61K | 1.49M | 709.15K | 14.52M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | AU$2.43B | 4.28 | -64.25% | 2.88% | 36.51% | 13.13% | |
46 Neutral | AU$304.18M | ― | -29.77% | ― | 6.07% | 59.09% | |
$81.49M | ― | -46.65% | ― | ― | ― | ||
$229.19M | ― | -31.16% | ― | ― | ― | ||
47 Neutral | AU$341.15M | ― | -524.68% | ― | 322.26% | -53.98% | |
43 Neutral | AU$89.40M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$130.39M | ― | -85.35% | ― | 315.11% | 51.16% |
Orthocell Limited announced a webinar to discuss the first US surgical use of Remplir™ and the progress of its rollout in the US. This development marks a significant step in Orthocell’s expansion strategy, potentially enhancing its market position in regenerative medicine and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has achieved a significant milestone with the first surgical use of its nerve repair product, Remplir™, in the United States, following FDA clearance. This marks a crucial step in penetrating the US$1.6 billion US nerve repair market, supported by a network of 14 specialist distributors. The successful surgery in Ohio highlights Orthocell’s commitment to expanding its market presence and driving sales growth, with expectations of increased revenue in the second half of 2025.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has announced compelling interim results from a study demonstrating the superiority of its Remplir product over traditional suture-only nerve repair techniques. The study, which supports the company’s US sales rollout, shows that Remplir leads to better nerve regeneration and earlier muscle function recovery, reducing adverse tissue reactions associated with sutures. These findings are expected to drive rapid market adoption and redefine the nerve repair market, with Orthocell targeting a total addressable market of over $3.5 billion across selected jurisdictions.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 1,367,852 new shares following the exercise of unlisted options, allowing immediate trading under the Corporations Act exemption. This move is part of Orthocell’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its stakeholders by increasing liquidity and financial flexibility.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the quotation of 1,367,852 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 10, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for further development and expansion of its regenerative medicine products.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has received regulatory approval to commence sales of its flagship nerve repair product, Remplir™, in Hong Kong, a strategically important market in the Asia Pacific region. This approval, granted ahead of schedule, adds to Orthocell’s growing portfolio of approvals in the US, Canada, Australia, New Zealand, Singapore, and Thailand, with further applications planned for the EU and UK. The company is leveraging external distributors to penetrate new markets while focusing internal resources on the US market. With a strong cash position and no debt, Orthocell is well-positioned to expand its commercial footprint and increase revenues.
Orthocell Ltd has rapidly expanded its US distribution network for its nerve repair product, Remplir™, appointing 12 distributors across 21 states, surpassing its initial target. This strategic expansion, following FDA clearance, is expected to significantly boost the company’s revenue and market penetration in the US$1.6 billion nerve repair market, leveraging experienced distributors and internal sales teams to drive growth.
Orthocell Limited has received regulatory approval from Health Canada to sell its nerve repair product, Remplir™, in the Canadian market, which is valued at US$75 million. This approval expands the total addressable market for Remplir to US$1.8 billion, following recent approvals in the US and Thailand, and existing approvals in Australia, New Zealand, and Singapore. The company plans to appoint local distributors in Canada to drive sales, with first sales expected in the second half of 2025. Orthocell is well-funded with A$31.7 million in cash reserves, positioning it to capitalize on these new market opportunities and continue its global expansion strategy.
Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development that could impact the company’s market positioning and stakeholder interests, as regulatory approvals are crucial for product commercialization and market expansion.
Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development for the company, potentially impacting its market position and stakeholder interests as it awaits the formal announcement.
Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.
Orthocell Limited has appointed its first four US distributors for its nerve repair product, Remplir™, following its recent FDA 510(k) clearance. This strategic move allows Orthocell to enter the US$1.6 billion US nerve repair market, with initial sales expected soon. The company plans to expand its distributor network to approximately 10 by mid-2025, covering around 25 states, to accelerate market penetration and revenue growth. Orthocell’s strong financial position and existing inventory support its US rollout, positioning it well for success in the competitive nerve repair industry.
Orthocell Limited has achieved a significant milestone with the US FDA 510(k) clearance for its nerve repair product, Remplir™, positioning the company to enter the lucrative US$1.6 billion nerve repair market. This clearance is expected to drive a substantial increase in revenue as the company has prepared logistics and sales pathways for its US launch. Additionally, Orthocell reported strong quarterly revenue growth, maintaining a robust cash position, and is expanding its market reach with regulatory applications in Canada and Thailand. The company’s inclusion in the S&P/ASX All Ordinaries Index further underscores its growing market presence.
Orthocell Limited has received regulatory approval from Brazil’s ANVISA for its dental regeneration product, Striate+, marking its first market authorization in Latin America. This approval is a strategic milestone for Orthocell, as Brazil represents a significant market opportunity and serves as a gateway for further expansion into Latin American countries. The approval follows the recent US FDA clearance for another product, Remplir, highlighting the company’s successful global commercialization efforts. With a strong balance sheet and a robust distribution partnership with BioHorizons, Orthocell is well-positioned to capitalize on the estimated US$735 million global market opportunity for Striate+, targeting a 20% market share.
Orthocell Limited announced the US FDA 510(k) clearance for its Remplir nerve repair product, marking a significant milestone for the company. This clearance is expected to enhance Orthocell’s market positioning in regenerative medicine, potentially benefiting stakeholders by expanding the product’s availability and application in the US market.
Orthocell Ltd has received US FDA 510(k) clearance for its nerve repair product, Remplir, allowing it to enter the US$1.6 billion US nerve repair market. This regulatory milestone is expected to significantly boost the company’s revenue and drive it towards profitability. Orthocell has prepared for this expansion with established logistics and sales pathways, a manufacturing facility capable of producing 100,000 units annually, and a strong cash reserve to support its US rollout and further market growth. The company aims to capture a meaningful market share without needing to displace existing dominant products, leveraging its proprietary manufacturing technology and strategic US commercial strategy.
Orthocell Limited has requested a trading halt on its securities pending an announcement regarding the results of its US FDA 510(k) clearance application. This clearance is crucial for the company as it seeks to commence commercial distribution in the US market, potentially impacting its market positioning and stakeholder interests.
Orthocell Limited announced that its CEO, Paul Anderson, will present at the HealthInvest 2025 conference in Sydney, highlighting the company’s progress and strategic initiatives. The presentation will include an update on the US FDA application for the Remplir nerve repair product, which signifies a critical step in Orthocell’s expansion efforts and could enhance its market positioning in regenerative medicine.